Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.

Matho MH, Schlossman A, Meng X, Benhnia MR, Kaever T, Buller M, Doronin K, Parker S, Peters B, Crotty S, Xiang Y, Zajonc DM.

PLoS Pathog. 2015 Sep 1;11(9):e1005148. doi: 10.1371/journal.ppat.1005148. eCollection 2015 Sep.

2.

BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge.

Franceschi V, Parker S, Jacca S, Crump RW, Doronin K, Hembrador E, Pompilio D, Tebaldi G, Estep RD, Wong SW, Buller MR, Donofrio G.

PLoS Negl Trop Dis. 2015 Jun 18;9(6):e0003850. doi: 10.1371/journal.pntd.0003850. eCollection 2015 Jun.

3.

Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes.

Irons EE, Flatt JW, Doronin K, Fox TL, Acchione M, Stewart PL, Shayakhmetov DM.

J Virol. 2013 Sep;87(17):9610-9. doi: 10.1128/JVI.01070-13. Epub 2013 Jun 26.

4.

The transcription factor IRF3 triggers "defensive suicide" necrosis in response to viral and bacterial pathogens.

Di Paolo NC, Doronin K, Baldwin LK, Papayannopoulou T, Shayakhmetov DM.

Cell Rep. 2013 Jun 27;3(6):1840-6. doi: 10.1016/j.celrep.2013.05.025. Epub 2013 Jun 13.

5.

Coagulation factor X activates innate immunity to human species C adenovirus.

Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M, Sumida JP, Ohto U, Shimizu T, Akashi-Takamura S, Miyake K, MacDonald JW, Bammler TK, Beyer RP, Farin FM, Stewart PL, Shayakhmetov DM.

Science. 2012 Nov 9;338(6108):795-8. doi: 10.1126/science.1226625. Epub 2012 Sep 27.

6.

Construction of targeted and armed oncolytic adenoviruses.

Doronin K, Shayakhmetov DM.

Methods Mol Biol. 2012;797:35-52. doi: 10.1007/978-1-61779-340-0_3.

PMID:
21948467
7.

Infection and killing of multiple myeloma by adenoviruses.

Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA.

Hum Gene Ther. 2010 Feb;21(2):179-90. doi: 10.1089/hum.2009.082.

8.

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

Shashkova EV, May SM, Doronin K, Barry MA.

Mol Ther. 2009 Dec;17(12):2121-30. doi: 10.1038/mt.2009.217. Epub 2009 Sep 15.

9.
10.

An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.

Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, Kuppuswamy M, Dhar D, Thomas MA, Tollefson AE, Zumstein LA, Wold WS, Toth K.

Cancer Gene Ther. 2009 Aug;16(8):644-54. doi: 10.1038/cgt.2009.5. Epub 2009 Feb 6.

11.

INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WS, Lichtenstein DL.

Cancer Gene Ther. 2009 Aug;16(8):625-37. doi: 10.1038/cgt.2009.6. Epub 2009 Feb 6.

12.

Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.

Shashkova EV, Doronin K, Senac JS, Barry MA.

Cancer Res. 2008 Jul 15;68(14):5896-904. doi: 10.1158/0008-5472.CAN-08-0488.

13.

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.

Shashkova EV, Kuppuswamy MN, Wold WS, Doronin K.

Cancer Gene Ther. 2008 Feb;15(2):61-72. Epub 2007 Nov 9.

14.

Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit.

Tollefson AE, Ying B, Doronin K, Sidor PD, Wold WS.

J Virol. 2007 Dec;81(23):12918-26. Epub 2007 Sep 19.

15.

Preparation and titration of CsCl-banded adenovirus stocks.

Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS.

Methods Mol Med. 2007;130:223-35.

PMID:
17401177
16.

Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic Adenovirus.

Shashkova EV, Spencer JF, Wold WS, Doronin K.

Mol Ther. 2007 Mar;15(3):598-607. doi: 10.1038/sj.mt.6300064. Epub 2016 Dec 8.

17.

Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.

Shashkova EV, Spencer JF, Wold WS, Doronin K.

Mol Ther. 2007 Mar;15(3):598-607. Epub 2006 Dec 26.

18.

Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.

Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K.

Gene Ther. 2005 Nov;12(22):1608-17.

PMID:
16034456
19.

Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.

Shashkova EV, Cherenova LV, Kazansky DB, Doronin K.

Cancer Gene Ther. 2005 Jul;12(7):617-26.

PMID:
15761475
20.

Cotton rat tumor model for the evaluation of oncolytic adenoviruses.

Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL, La Regina MC, Prince GA, Wold WS.

Hum Gene Ther. 2005 Jan;16(1):139-46.

PMID:
15703497
21.

Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice.

Toth K, Doronin K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS.

Virus Res. 2005 Mar;108(1-2):149-59.

PMID:
15681065
22.

Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Lichtenstein DL, Doronin K, Toth K, Kuppuswamy M, Wold WS, Tollefson AE.

J Virol. 2004 Nov;78(22):12297-307.

23.

An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling.

Toth K, Djeha H, Ying B, Tollefson AE, Kuppuswamy M, Doronin K, Krajcsi P, Lipinski K, Wrighton CJ, Wold WS.

Cancer Res. 2004 May 15;64(10):3638-44.

24.

Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo.

Cherenova LV, Logunov DY, Shashkova EV, Shmarov MM, Verkhovskaya LV, Neugodova GL, Kazansky DB, Doronin KK, Naroditsky BS.

Virus Res. 2004 Mar 15;100(2):257-61.

PMID:
15019245
25.

Functions and mechanisms of action of the adenovirus E3 proteins.

Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS.

Int Rev Immunol. 2004 Jan-Apr;23(1-2):75-111. Review.

PMID:
14690856
26.

A multitasking oncolytic adenovirus vector.

Toth K, Doronin K, Tollefson AE, Wold WS.

Mol Ther. 2003 Apr;7(4):435-7. No abstract available.

27.

Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.

Toth K, Tarakanova V, Doronin K, Ward P, Kuppuswamy M, Locke JE, Dawson JE, Kim HJ, Wold WS.

Cancer Gene Ther. 2003 Mar;10(3):193-200.

PMID:
12637940
28.

Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus.

Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WS.

Virology. 2003 Jan 20;305(2):378-87.

29.

[Delivery of secreted placental alkaline phosphatase (SEAP) gene in vitro and in vivo as a component of recombinant avian adenovirus (CELO)].

Logunov DIu, Cherenova LV, Shmarov MM, Shashkova EV, Verkhovskaia LV, Doronin KK, Naroditskiĭ BS.

Mol Gen Mikrobiol Virusol. 2002;(4):21-5. Russian.

PMID:
12534266
30.

Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region.

Toth K, Kuppuswamy M, Doronin K, Doronina O, Lichtenstein D, Tollefson A, Wold W.

Virology. 2002 Sep 15;301(1):99-108.

31.

[Eukaryotic vectors of Celo avian adenovirus genome, carrying GFP and human IL-2 genes].

Shmarov MM, Cherenova LV, Shashkova EV, Logunov DIu, Verkhovskaia LV, Kapitonov AV, Neugodova GL, Doronin KK, Naroditskiĭ BS.

Mol Gen Mikrobiol Virusol. 2002;(2):30-5. Russian.

PMID:
12180023
32.

Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc).

Habib NA, Mitry R, Seth P, Kuppuswamy M, Doronin K, Toth K, Krajcsi P, Tollefson AE, Wold WS.

Cancer Gene Ther. 2002 Aug;9(8):651-4.

33.

Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.

Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, Lichtenstein DL, Hermiston TW, Smith CA, Wold WS.

J Virol. 2001 Oct;75(19):8875-87.

34.

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.

Doronin K, Kuppuswamy M, Toth K, Tollefson AE, Krajcsi P, Krougliak V, Wold WS.

J Virol. 2001 Apr;75(7):3314-24.

35.

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein.

Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS.

J Virol. 2000 Jul;74(13):6147-55.

36.

[Early transcription of FAV-1 (CELO) avian adenovirus genome].

Tikhomirov EE, Baburina TM, Neugodova GL, Doronin KK, Zakharchuk AN.

Vopr Virusol. 1998 Nov-Dec;43(6):279-83. Russian.

PMID:
10488533
37.

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE.

Curr Opin Immunol. 1999 Aug;11(4):380-6. Review.

PMID:
10448144
38.

[Structural and functional organization of avian adenovirus EDS-76 genome. Sequencing and analysis of the 0-10.6% fragment of viral DNA].

Akopian TA, Doronin KK, Zakharchuk AN, Lazarev VN, Verkhovskaia LV, Vasil'ev SA, Naroditskiĭ BS.

Mol Biol (Mosk). 1998 May-Jun;32(3):420-6. Russian. No abstract available.

PMID:
9720064
39.

[Expression of the ribozyme gene in the recombinant defective adenovirus genome].

Zakharchuk AN, Doronin KK, Baburina TM, Lazaref VN, Naroditskiĭ BS.

Mol Biol (Mosk). 1997 Jan-Feb;31(1):81-5. Russian. No abstract available.

PMID:
9173251
40.

Sequence of the avian adenovirus FAV 1 (CELO) DNA encoding the hexon-associated protein pVI and hexon.

Akopian TA, Doronin KK, Karpov VA, Naroditsky BS.

Arch Virol. 1996;141(9):1759-65.

PMID:
8893797
41.

[Expression of a gene encoding the porcine rotavirus VP7 capsid using a nondefective recombinant adenoviral genome].

Doronin KK, Iurov GK, Grinenko NF, Zakharchuk AN, Denisova TS, Baburina TM, Krugliak VA, Naroditskiĭ BS.

Mol Gen Mikrobiol Virusol. 1995 Oct-Dec;(4):35-9. Russian.

PMID:
8604234
42.

The fowl adenovirus type 1 (CELO) virus-associated RNA-encoding gene: a new ribozyme-expression vector.

Zakharchuk AN, Doronin KK, Karpov VA, Krougliak VA, Naroditsky BS.

Gene. 1995 Aug 19;161(2):189-93.

PMID:
7665077
43.

[In vitro and in vivo study of the activity of secreted alkaline phosphatase mRNA ribozyme gene].

Zakharchuk AN, Doronin KK, Karpov VA, Krugliak VA, Naroditskiĭ BS.

Mol Gen Mikrobiol Virusol. 1994 Nov-Dec;(6):8-12. Russian.

PMID:
7739597
44.

Expression of the gene encoding secreted placental alkaline phosphatase (SEAP) by a nondefective adenovirus vector.

Doronin KK, Zakharchuk AN, Grinenko NF, Yurov GK, Krougliak VA, Naroditsky BS.

Gene. 1993 Apr 30;126(2):247-50.

PMID:
8482541
45.

[Preparation of a non-defective adenovirus vector based on the Ad5 genome with the E3 region replaced with plasmid DNA with a kanamycin- resistance gene].

Doronin KK, Krugliak VA, Grinenko NF, Progonova EV, Grodnitskaia NA, Naroditskiĭ BS, Tikhonenko TI.

Mol Gen Mikrobiol Virusol. 1993 Jan-Feb;(1):31-5. Russian.

PMID:
8510682

Supplemental Content

Loading ...
Support Center